Aminoacyl-tRNA synthetase inhibitors as antimicrobial agents: a patent review from 2006 till present

Bibliography

• Schimmel P, Tao J, Hill J. Aminoacyl tRNA synthetases as targets for new anti-infectives. FASEB J 1998;12:1599-609
   PubMed Web of Science ®Google Scholar
• Rock FL, Mao W, Yaremchuk A, An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007;316:1759-61
   PubMed Web of Science ®Google Scholar
• Ibba M, Soll D. Aminoacyl-tRNA Synthesis. Ann Rev Biochem 2000;69:617-50
   PubMed Web of Science ®Google Scholar
• Schimmel P, Soll D. Aminoacyl-tRNA synthetases: general features and recognition of transfer RNAs. Ann Rev Biochem 1979;48:601-48
   PubMed Web of Science ®Google Scholar
• Delarue M. Aminoacyl-tRNA synthetases. Curr Opin Struct Biol 1995;5:48-55
   PubMed Web of Science ®Google Scholar
• Vondenhoff GHM, Van Aerschot A. Aminoacyl-tRNA synthetase inhibitors as potential antibiotics. Eur J Med Chem 2011;46:5227-36
   PubMed Web of Science ®Google Scholar
• Cusack S. Aminoacyl-tRNA synthetases. Curr Opin Struct Biol 1997;7:881-9
   PubMed Web of Science ®Google Scholar
• Ataide SF, Ibba M. Small molecules: big players in the evolution of protein synthesis. ACS Chem Biol 2006;1:285-97
   Google Scholar
• Park SG, Schimmel P, Kim S. Aminoacyl tRNA synthetases and their connections to disease. Proc Natl Acad Sci 2008;105:11043-9
   PubMed Web of Science ®Google Scholar
• Ibba M, Curnow AW, Soll D. Aminoacyl-tRNA synthesis: divergent routes to a common goal. Trends Biochem Sci 1997;22:39-42
   Google Scholar
• Doolittle WF, Brown JR. Tempo, mode, the progenote, and the universal root. Proc Natl Acad Sci 1994;91:6721-8
   PubMed Web of Science ®Google Scholar
• Brown JR, Doolittle WF. Root of the universal tree of life based on ancient aminoacyl-tRNA synthetase gene duplications. Proc Natl Acad Sci 1995;92:2441-5
   PubMed Web of Science ®Google Scholar
• Eriani G, Delarue M, Poch O, Partition of tRNA synthetases into two classes based on mutually exclusive sets of sequence motifs. Nature 1990;347:203-6
   PubMed Web of Science ®Google Scholar
• Cusack S, Hartlein M, Leberman R. Sequence, structural and evolutionary relationships between class 2 aminoacyl-tRNA synthetases. Nucleic Acids Res 1991;19:3489-98
   PubMedGoogle Scholar
• Rao ST, Rossmann MG. Comparison of super-secondary structures in proteins. J Mol Biol 1973;76:241-56
   PubMed Web of Science ®Google Scholar
• Ochsner UA, Sun X, Jarvis T, Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents. Expert Opin Investig Drugs 2007;16:573-93
   PubMed Web of Science ®Google Scholar
• Hurdle JG, O'Neill AJ, Chopra I. Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob Agents Chemother 2005;49:4821-33
   PubMed Web of Science ®Google Scholar
• Kim S, Lee SW, Choi EC, Choi SY. Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics. Appl Microbiol Biotechnol 2003;61:278-88
   PubMed Web of Science ®Google Scholar
• Tao J, Wendler P, Connelly G, Drug target validation: lethal infection blocked by inducible peptide. Proc Natl Acad Sci 2000;97:783-6
   PubMed Web of Science ®Google Scholar
• Raczniak G, Ibba M, Soll D. Genomics-based identification of targets in pathogenic bacteria for potential therapeutic and diagnostic use. Toxicology 2001;160:181-9
   Google Scholar
• Bunk DM, Dalluge JJ, Welch MJ. Heterogeneity in human cardiac troponin I standards. Anal Biochem 2000;284:191-200
   PubMedGoogle Scholar
• Ibba M, Francklyn C, Cusack S. The aminoacyl-tRNA synthetases. Landes Bioscience/Eurekah.com; Georgetown, Texas, USA. 2005
   Google Scholar
• Pohlmann J, Brotz-Oesterhelt H. New aminoacyl-tRNA synthetase inhibitors as antibacterial agents. Curr Drug Targets Infect Disord 2004;4:261-72
   PubMedGoogle Scholar
• Hughes J, Mellows G, Soughton S. How does pseudomonas fluorescens, the producing organism of the antibiotic pseudomonic acid A, avoid suicide? FEBS Lett 1980;122:322-4
   PubMedGoogle Scholar
• Yanagisawa T, Lee JT, Wu HC, Kawakami M. Relationship of protein structure of isoleucyl-tRNA synthetase with pseudomonic acid resistance of Escherichia coli. A proposed mode of action of pseudomonic acid as an inhibitor of isoleucyl-tRNA synthetase. J Biol Chem 1994;269:24304-9
   Google Scholar
• Silvian LF, Wang J, Steitz TA. Insights into editing from an Ile-tRNA synthetase structure with tRNAIle and mupirocin. Science 1999;285:1074-7
   PubMed Web of Science ®Google Scholar
• Pappa KA. The clinical development of mupirocin. J Am Acad Dermatol 1990;22:873-9
   PubMed Web of Science ®Google Scholar
• Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clinical Infect Dis 2009;49:935-41
   PubMed Web of Science ®Google Scholar
• Werner RG, Thorpe LF, Reuter W, Nierhaus KH. Indolmycin inhibits prokaryotic tryptophanyl-tRNA ligase. Eur J Biochem 1976;68:1-3
   PubMedGoogle Scholar
• Kitabatake M, Ali K, Demain A, Indolmycin resistance of Streptomyces coelicolor A3(2) by Induced expression of one of Its two tryptophanyl-tRNA synthetases. J Biol Chem 2002;277:23882-7
   PubMed Web of Science ®Google Scholar
• Hurdle JG, O'Neill AJ, Chopra I. Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections. J Antimicrob Chemother 2004;54:549-52
   PubMed Web of Science ®Google Scholar
• Kanamaru T, Nakano Y, Toyoda Y, In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. Antimicrob Agents Chemother 2001;45:2455-9
   PubMed Web of Science ®Google Scholar
• Vino S, Lokesh KR. Borrelidin: a promising anticancer agent from Streptomyces species. Adv Biotech 2008;6:22-6
   Google Scholar
• Olano C, Moss SJ, Brana AF, Biosynthesis of the angiogenesis inhibitor borrelidin by Streptomyces parvulus Tu4055: insights into nitrile formation. Mol Microbiol 2004;52:1745-56
   Google Scholar
• Kuo MS, Yurek DA, Kloosterman DA. Assignment of 1H and 13C NMR signals and the alkene geometry at C-7 in borrelidin. J Antibiot (Tokyo) 1989;42:1006-7
   Google Scholar
• Ruan BF, Bovee ML, Sacher M, A unique hydrophobic cluster near the active site contributes to differences in borrelidin inhibition among threonyl-tRNA synthetases. J Biol Chem 2005;280:571-7
   PubMed Web of Science ®Google Scholar
• Paetz W, Nass G. Biochemical and immunological characterization of threonyl-tRNA synthetase of two borrelidin-resistant mutants of Escherichia coli. Eur J Biochem 1973;35:331-7
   PubMedGoogle Scholar
• Nass G, Poralla K, Zahner H. Effect of the antibiotic borrelidin on the regulation of threonine biosynthetic enzymes in E. coli. Biochem Biophys Res Commun 1969;34:84-91
   PubMed Web of Science ®Google Scholar
• Gerken SC, Arfin SM. Chinese hamster ovary cells resistant to borrelidin overproduce threonyl-tRNA synthetase. J Biol Chem 1984;259:9202-6
   PubMed Web of Science ®Google Scholar
• Kazakov T, Vondenhoff GH, Datsenko KA, Escherichia coli peptidase A, B, or N can process translation inhibitor microcin C. J Bacteriol 2008;190:2607-10
   PubMed Web of Science ®Google Scholar
• Tikhonov A, Kazakov T, Semenova E, The mechanism of microcin C resistance provided by the MccF peptidase. J Biol Chem 2010;285:37944-52
   PubMed Web of Science ®Google Scholar
• Novikova M, Metlitskaya A, Datsenko K, The Escherichia coli Yej transporter is required for the uptake of translation inhibitor microcin C. J Bacteriol 2007;189:8361-5
   PubMed Web of Science ®Google Scholar
• Van de Vijver P, Vondenhoff GHM, Kazakov TS, Synthetic microcin C analogs targeting different aminoacyl-tRNA synthetases. J Bacteriol 2009;191:6273-80
   PubMed Web of Science ®Google Scholar
• Zeng Y, Roy H, Patil PB, Characterization of two seryl-tRNA synthetases in albomycin-producing streptomyces sp. Strain ATCC 700974. Antimicrob Agents Chemother 2009;53:4619-27
   Google Scholar
• Gause GF. Recent studies on albomycin, a new antibiotic. Br Med J 1955;2:1177-9
   Google Scholar
• Pramanik A, Stroeher UH, Krejci J, Albomycin is an effective antibiotic, as exemplified with Yersinia enterocolitica and Streptococcus pneumoniae. Int J Med Microbiol 2007;297:459-69
   PubMed Web of Science ®Google Scholar
• Hoepfner D, McNamara CW, Lim CS, Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe 2012;11:654-63
   PubMed Web of Science ®Google Scholar
• Anke H. Metabolic products of microorganisms. 184. On the mode of action of cladosporin. J Antibiot (Tokyo) 1979;32:952-8
   PubMed Web of Science ®Google Scholar
• Forrest A, Osborne NF, Pengelly D; inventors. Mupirocinsulfamates with antibacterial activity. WO005126A1; 1997
   Google Scholar
• Forrest AK, Jarvest RL, Mensah LM, Aminoalkyl adenylate and aminoacyl sulfamate intermediate analogues differing greatly in affinity for their cognate Staphylococcus aureus aminoacyl tRNA synthetases. Bioorg Med Chem Lett 2000;10:1871-4
   PubMed Web of Science ®Google Scholar
• Hill JM, Yu G, Zydowsky TM, Rebek J; inventors; Cubist Pharmaceuticals, Inc., assignee. Aminoacyl adenylate mimics as novel anitmicrobial and antiparasitic agents. US5726195; 1998
   Google Scholar
• Farrera-Sinfreu J, Espanol Y, Geslain R, Solid-phase combinatorial synthesis of a lysyl-tRNA synthetase (LysRS) inhibitory library. J Comb Chem 2008;10:391-400
   Google Scholar
• Bennett I, Broom NJP, Cassels R, Synthesis and antibacterial properties of beta-diketone acrylate bioisosteres of pseudomonic acid A. Bioorg Med Chem Lett 1999;9:1847-52
   PubMed Web of Science ®Google Scholar
• Brown MJB, Mensah LM, Doyle ML, Rational design of femtomolar inhibitors of isoleucyl tRNA synthetase from a binding model for pseudomonic acid-A. Biochemistry 2000;39:6003-11
   PubMed Web of Science ®Google Scholar
• Konishi M, Nishio M, Saitoh K, Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure. J Antibiot 1989;42:1749-55
   PubMed Web of Science ®Google Scholar
• Mittendorf J, Kunisch F, Matzke M, Novel antifungal beta-amino acids: synthesis and activity against Candida albicans. Bioorg Med Chem Lett 2003;13:433-6
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Kelaher AM, Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2005;49:2084-92
   PubMed Web of Science ®Google Scholar
• Hasenoehrl A, Galic T, Ergovic G, In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans. Antimicrob Agents Chemother 2006;50:3011-18
   PubMed Web of Science ®Google Scholar
• Critchley IA, Green LS, Young CL, Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections. J Antimicrob Chemother 2009;63:954-63
   PubMed Web of Science ®Google Scholar
• Shibata S, Gillespie JR, Kelley AM, Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. Antimicrob Agents Chemother 2011;55:1982-9
   PubMed Web of Science ®Google Scholar
• Shibata S, Gillespie JR, Ranade RM, Urea-Based Inhibitors of Trypanosoma brucei Methionyl-tRNA Synthetase: selectivity and in Vivo Characterization. J Med Chem 2012;55:6342-51
   PubMed Web of Science ®Google Scholar
• Balg C, De Mieri M, Huot JL, Inhibition of Helicobacter pylori aminoacyl-tRNA amidotransferase by chloramphenicol analogs. Bioorg Med Chem 2010;18:7868-72
   Google Scholar
• Das B, Arora JS, Ahmed S, inventors; Ranbaxy Laboratories Limited, assignee. Antimicrobial agents. WO117762A2; 2006
   Google Scholar
• Das B, Arora JS, Ahmed S, inventors; Ranbaxy Laboratories Limited, assignee. Antimicrobial agents. US0215764A1; 2009
   Google Scholar
• Das B, Upadhyay DJ, Purnapatre K, inventors; Ranbaxy Laboratories Limited, assignee. Heterocyclic sulfonamides as inhibitors of transfer RNA synthetase for use as antibacterial agents. WO014109A1; 2012
   Google Scholar
• Ahmed S, Das B, Upadhyay DJ; inventors; Ranbaxy Laboratories Limited,assignee. Isoindole derivatives as antimicrobial agents. WO029076A1; 2007
   Google Scholar
• Baker SJ, Akama T, Carolyn BK, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. US7582621B2; 2009
   Google Scholar
• Baker SJ, Akama T, Carolyn BK, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. US8039451B2; 2011
   Google Scholar
• Baker SJ, Akama T, Carolyn BK, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. WO0234981A1; 2006
   Google Scholar
• Baker SJ, Akama T, Alley MRK, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. US8115026B2; 2012
   Google Scholar
• Baker SJ, Tsutomu A, Carolyn BK, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. US0319361A1; 2011
   Google Scholar
• Baker SJ, Akama T, Alley MRK, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. WO0155699A1; 2007
   Google Scholar
• Baker SJ, Akama T, Alley MRK, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. WO078340A2; 2007
   Google Scholar
• Baker SJ, Hernandez VS, Sharma R, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. US7816344B2; 2010
   Google Scholar
• Baker SJ, Hernandez VS, Sharma R, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. WO157726A1; 2008
   Google Scholar
• Zhou H, Ding D, Zhou Y, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules as antiprotozoal agents. WO022337A1; 2011
   Google Scholar
• Hernandez V, Ding C, Plattner J, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. WO037731A1; 2011
   Google Scholar
• Hernandez VS, Ding C, Plattner J, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. US0124597; 2011
   Google Scholar
• Hernandez VS, Li X, Zhang S, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. WO060199A1; 2011
   Google Scholar
• Guiles J, Xicheng S, Janjic N, Strong S; inventors; Replidyne, Inc., assignee. Substituted phenylether-thienopyridone compounds with antibacterial activity. WO039641A2; 2008
   Google Scholar
• Guiles J, Sun X, Janjic N, Strong S; inventors; Replidyne, Inc., assignee. Substituted phenylether-thienopyridone compounds with antibacterial activity. US0227808A1; 2008
   Google Scholar
• Guiles J, Sun X, Janjic N, Strong S; inventors; Crestone, Inc., assignee. Substituted thienopyridone compounds with antibacterial activity. US7994192B2; 2011
   Google Scholar
• Guiles J, Sun X, Janjic N, Strong S; inventors; Replidyne, Inc., assignee. Substituted thienopyridone compounds with antibacterial activity. WO039639A2; 2008
   Google Scholar
• Guiles J, Sun X, Janjic N, Strong S; inventors; Replidyne, Inc., assignee. Substituted-thienopyridone compounds with antibacterial activity. WO0146609A1; 2008
   Google Scholar
• Guiles J, Sun X, Janjic N, inventors; Replidyne, Inc., assignee. Enantiomeric compounds with antibacterial activity. WO039640A2; 2008
   Google Scholar
• Guiles J, Sun X, Janjic N, inventors; Crestone, Inc., assignee. Enantiomeric compounds with antibacterial activity. US7973050B2; 2011
   Google Scholar
• Guiles J, Sun X, Janjic N, Strong S; inventors; Replidyne, Inc., assignee. Methods and compositions for treatment of Clostridium based infection. WO039642A2; 2008
   Google Scholar
• Mayer FK; inventor; Novartis AG, assignee. Pharmaceutical compositions for the treatment of fungal infections. WO025543A1; 2008
   Google Scholar
• Sello JK, Vecchione JJ; inventors; Brown University, assignee. Combination of an aminoacyl-tRNA synthetase inhibitor with a further antibacterial agents for attenuating multiple drug resistance. WO054738A1; 2012
   Google Scholar